Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CD19/BCMA CAR T-cells in Relapsed/Refractory Myasthenia Gravis
NCT06933563Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in myasthenia gravis (MG), sponsored by Zhejiang University. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 90 days and 2 more. Planned start Apr 2025; status: not yet recruiting.
02
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06933563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933563.